New pyridobenzodiazepine derivatives: Modifications of the basic side chain differentially modulate binding to dopamine (D4.2, D2L) and serotonin (5-HT2A) receptors

Journal of Medicinal Chemistry

Volumn 45, Issue 23, 2002, Pages 5136-5149

  Liégeois, Jean François ^a   Eyrolles, Laurence ^a   Ellenbroek, Bart A ^b   Lejeune, Christel ^c   Carato, Pascal ^a   Bruhwyler, Jacques ^d   Géczy, Joseph ^d   Damas, Jacques ^a   Delarge, Jacques ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c Facultes Universitaires Notre Dame de la Paix Faculte de Medicine   (Belgium)

^d Therabel Pharma Belgium   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 6 (4 BENZYL 1 PIPERAZINYL) 11H PYRIDO[2,3 B][1,4]BENZODIAZEPINE; 8 CHLORO 6 (4 CYCLOHEXYL 1 PIPERAZINYL) 11H PYRIDO[2,3 B][1,4]BENZODIAZEPINE; 8 CHLORO 6 (4 METHYL 1 HOMOPIPERAZINYL) 11H PYRIDO[2,3 B][1,4]BENZODIAZEPINE; 8 CHLORO 6 (4 METHYL 1 PIPERAZINYL) 11H PYRIDO[2,3 B][1,4]BENZODIAZEPINE; 8 CHLORO 6 (4 PHENETHYL 1 PIPERAZINYL) 11H PYRIDO[2,3 B][1,4]BENZODIAZEPINE; 8 CHLORO 6 (4 PHENYL 1 PIPERAZINYL) 11H PYRIDO[2,3 B]BENZODIAZEPINE; 8 CHLORO 6 [(1 BENZYL 4 PIPERIDINYL)AMINO] 11H PYRIDO[2,3 B][1,4]BENZODIAZEPINE; 8 CHLORO 6 [(1 METHYL 4 PIPERIDINYL)AMINO] 11H PYRIDO[2,3 B][1,4]BENZODIAZEPINE; 8 CHLORO 6 [4 (3 CHLOROPHENYL) 1 PIPERAZINYL] 11H PYRIDO[2,3 B]BENZODIAZEPINE; 8 CHLORO 6 [4 (3 TRIFLUOROMETHYLPHENYL) 1 PIPERAZINYL] 11H PYRIDO[2,3 B][1,4]BENZODIAZEPINE; 8 METHYL 6 (4 BENZYL 1 PIPERAZINYL) 11H PYRIDO[2,3 B][1,4]BENZODIAZEPINE; 8 METHYL 6 (4 CYCLOHEXYL 1 PIPERAZINYL) 11H PYRIDO[2,3 B][1,4]BENZODIAZEPINE; 8 METHYL 6 (4 METHYL 1 HOMOPIPERAZINYL) 11H PYRIDO[2,3 B][1,4]BENZODIAZEPINE; 8 METHYL 6 (4 METHYL 1 PIPERAZINYL) 11H PYRIDO[2,3 B][1,4]BENZODIAZEPINE; 8 METHYL 6 (4 PHENETHYL 1 PIPERAZINYL) 11H PYRIDO[2,3 B][1,4]BENZODIAZEPINE; 8 METHYL 6 (4 PHENYL 1 PIPERAZINYL) 11H PYRIDO[2,3 B][1,4]BENZODIAZEPINE; 8 METHYL 6 [(1 BENZYL 4 PIPERIDINYL)AMINO] 11H PYRIDO[2,3 B][1,4]BENZODIAZEPINE; 8 METHYL 6 [(1 METHYL 4 PIPERIDINYL)AMINO] 11H PYRIDO[2,3 B][1,4]BENZODIAZEPINE; 8 METHYL 6 [4 (3 CHLOROPHENYL) 1 PIPERAZINYL] 11H PYRIDO[2,3 B][1,4]BENZODIAZEPINE; 8 METHYL 6 [4 (3 TRIFLUOROMETHYLPHENYL) 1 PIPERAZINYL] 11H PYRIDO[2,3 B][1,4]BENZODIAZEPINE; ANTIDEPRESSANT AGENT; BICYCLO[3.2.1]OCTANE DERIVATIVE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; HALOPERIDOL; PIPERAZINE DERIVATIVE; PYRIDOBENZODIAZEPINE DERIVATIVE; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALKALINITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CATALEPSY; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG CONFORMATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; IMMOBILIZATION; MOUSE; NONHUMAN; PSYCHOPHARMACOLOGY; RAT; RIGIDITY;

AMINES; ANIMALS; ANTIDEPRESSIVE AGENTS; BENZODIAZEPINES; CATALEPSY; CELL LINE; DOPAMINE AGENTS; FEMALE; HUMANS; MICE; MOLECULAR CONFORMATION; PIPERAZINES; PIPERIDINES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; RECEPTORS, SEROTONIN; SEROTONIN AGENTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037038334     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0104825     Document Type: Article

References (88)

1. Love, R. C.; Nelson, M. W. Pharmacology and clinical experience with risperidone. Exp. Opin. Pharmacother. 2000, 1, 1441-1453.
2. Brown, L. A.; Levin, G. M. Sertindole, a new atypical antipsychotic for the treatment of schizophrenia. Pharmacotherapy 1998, 18, 69-83.
3. Kane, J. M. Sertindole: A review of clinical efficacy. Int. Clin. Psychopharmacol. 1998, 13, S59-S63.
4. Bhana, N.; Foster, R. H.; Olney, R.; Plosker, G. L. Olanzapine. An updated review of its use in the management of schizophrenia. Drugs 2001, 61, 111-161.
5. Fulton, B.; Goa, K. L. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 1997, 53, 281-298.
6. Goldstein, J. M. Quetiapine fumarate (Seroquel): A new atypical antipsychotic. Drugs Today 1999, 35, 193-210.
7. Kasper, S.; Müller-Spahn, F. Review of quetiapine and its clinical applications in schizophrenia. Exp. Opin. Pharmacother. 2000, 1, 783-801.
8. Tandon, R.; Harrigan, E.; Zorn, S. H. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential. J. Serotonin Res. 1997, 4, 159-177.
9. Cooper, S. J.; Tweed, J.; Raniwalla, J.; Butler, A.; Welch, C. A placebo-controlled comparison of zotepine versus chlropromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatr. Scand. 2000, 101, 218-225.
10. Kane, J.; Honigfeld, G.; Singer, J.; Meltzer, H. Clozapine for the treatment-resistant schizophrenic. A double blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45, 789-796.
11. Meltzer, H. Y.; Okayli, G. Reduction of suicidality during clozapine treatment of neuroleptic resistant schizophrenia: Impact on risk-benefit assessment. Am. J. Psychiatry 1995, 152, 183-190.
12. Haller, E.; Binder, R. L. Clozapine and seizures. Am. J. Psychiatry 1990, 147, 1069-1071.
13. Copp, P. J.; Lament, R.; Tennent, T. G. Amitriptyline in clozapine-induced sialorrhea. Br. J. Psychiatry 1991, 159, 166.
14. Cunningham Owens, D. G. Adverse effects of antipsychotic agents. Do newer agents offer advantages? Drugs 1996, 51, 895-930.
15. Lieberman, J. A.; Johns, C. A.; Kane, J. M.; Rai, K.; Pisciotta, A. V.; Saltz B. L.; Howard, A. Clozapine-induced agranulocytosis: Non-cross reactivity with other psychotropic drugs. J. Clin. Psychiatry 1988, 49, 271-277.
16. Grohmann, R.; Schmidt, L. G.; Spieb-Kiefer, C.; Rüther, E. Agranulocytosis and significant leucopenia with neuroleptic drugs: Results from the AMÜP program. Psychopharmacology 1989, 99, S109-S112.
17. Pisciotta, A. V. Drug induced agranulocytosis peripheral destruction of polymorphonuclear leukocytes and their marrow precursors. Blood Rev. 1990, 4, 226-237.
18. Bürki, H. R.; Sayer, A. C.; Ruch, W.; Asper, H. Effects of clozapine and other dibenzo-epines on central dopaminergic and cholinergic systems. Structure-activity relationships. Arzneimittelforschung 1977, 27, 1561-1565.
19. i values. J. Pharmacol. Exp. Ther. 1989, 251, 238-246.
20. Richelson, E.; Souder, T. Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sci. 2000, 68, 29-39.
21. Schotte, A.; Janssen, P. F. M.; Gommeren, W.; Luyten, W. H. M. L.; Gompel, P. V.; Lesage, A. S.; De Loore, K.; Leysen, J. E. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology 1996, 124, 57-73.
22. Chakrabarti, J. K.; Hotten, T. M.; Pullar, I. A.; Steggles, D. J. Synthesis and pharmacological evaluation of CNS activities of [1,2,3]triazolo[4,5-b][1,5]-, imidazolo[4,5-b][1,5]-, and pyrido[2,3-b][1,5]benzodiazepines. 10-Piperazinyl-4H-1,2,3-triazolo[4,5-b]-[1,5]benzodiazepines with neuroleptic activity. J. Med. Chem. 1989, 32, 2375-2381.
23. Leysen, J. E.; Niemegeers, C. J. E.; Tollenaere, J. P.; Laduron, P. Serotonergic component of neuroleptic receptors. Nature 1978, 272, 168-171.
24. Waldmeier, P. C.; Delini-Stula, A. A. Serotonin-dopamine interactions in the nigrostriatal system. Eur. J. Pharmacol. 1979, 55, 363-373.
25. 2 antagonists modulates the effects of D-2 dopamine receptor blockade. J. Pharmacol. Exp. Ther. 1990, 253, 1162-1170.
26. 2A receptor antagonist MDL 100,907. Biol. Psychiatry 1998, 44, 508-515.
27. 2 antagonists. 2. Substituted 3-(4-fluorophenyl)-1H-indoles. J. Med. Chem. 1992, 35, 4823-4831.
28. 2 antagonism in a series of 5-substituted trans-1-piperazino-3-phenylindans. J. Med. Chem. 1993, 36, 2761-2770.
29. Campiani, G.; Nacci, V.; Bechelli, S.; Ciani, S. M.; Garofalo, A.; Fiorini, I.; Wikström, H.; de Boer, P.; Liao, Y.; Tepper, P. G.; Cagnotto, A.; Mennini, T. New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo- [2,1-b][1,3]benzothiazepine structure. J. Med. Chem. 1998, 41, 3763-3772.
30. 2 ratio hypotheses. Curr. Med. Chem. 1994, 1, 50-60.
31. 2 antagonists within a series of 3-substituted 1-(4-fluorophenyl)-1H-indoles. J. Med. Chem. 1992, 35, 1092-1101.
32. Meltzer, H. Y. Multireceptor atypical antipsychotic drugs. In Atypical Antipsychotics; Ellenbroek, B. A., Cools, A. R., Eds.; Birrkhaüser Verlag: Basel (CH), 2000; pp 191-213.
33. Stahl, S. M. Antipsychotic agents. In Essential Psychopharmacology. Neuroscientific Basis and Practical Applications, 2nd Ed.; Cambridge University Press: Cambridge, 2000; pp 401-458.
34. 4 receptor with high affinity for the antipsychotic clozapine. Nature 1991, 350, 610-614.
35. 4 receptor: A controversial therapeutic target. Drugs Future 2000, 25, 587-611.
36. Kebabian, J. W.; Tarazi, F. I.; Kula, N. S.; Baldessarini, R. J. Compounds selective for dopamine receptor subtypes. Drug Discov. Todays 1997, 2, 333-340.
37. 4 receptors, a new opportunity for research on schizophrenia. Curr. Med. Chem. 1998, 5, 77-100.
38. 4 receptor: One decade of research. Eur. J. Pharmacol. 2000, 405, 303-327.
39. 4 receptors: Basic and clinical status. Int. J. Neuropsychopharmacol. 1999, 2, 41-58.
40. Liégeois, J.-F.; Bruhwyler, J.; Rogister, F.; Delarge, J. Diarylazepine derivatives as potent atypical neuroleptic drugs: Recent advances. Curr. Med. Chem. 1995, 1, 471-501.
41. Leysen, J. E.; Janssen, P. M. F.; Heylen, L.; Gommeren, W.; Van Gompel, P.; Lesage, A. S., Megens, A. A. H. P.; Schotte, A. Receptor interactions of new antipsychotics: Relation to pharmacodynamic and clinical effects. Int. J. Psychiatry Clin. Pract. 1998, 2, S3-S17.
42. Schmutz, J.; Picard, C. W. Tricyclic neuroleptics: Structure-activity relationships. Handbook Exp. Pharmacol. 1986, 55, 3-25.
43. Liao, Y.; DeBoer, P.; Meier, E.; Wikström, H. Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: Identification of a novel atypical neuroleptic. J. Med. Chem. 1997, 40, 4146-4153.
44. Liao, Y.; Venhuis, B. J., Rodenhuis, N.; Timmerman, W.; Wikström, H. New(sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: Chemistry and pharmacological evaluation. J. Med. Chem. 1999, 42, 2235-2244.
45. Liégeois, J.-F.; Bruhwyler, J.; Damas, J.; Nguyen, T. P.; Chleide, E.; Mercier, M.; Rogister, F.; Delarge, J. New pyridobenzodiazepine derivatives as potential antipsychotics: Synthesis and neurochemical study. J. Med. Chem. 1993, 36, 2107-2114.
46. Liégeois, J.-F.; Rogister, F.; Bruhwyler, J.; Damas, J.; Nguyen, T. P.; Inarejos, M. O.; Chleide, E.; Mercier, M.; Delarge, J. Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: Synthesis and neurochemical study. J. Med. Chem. 1994, 37, 519-525.
47. Liégeois, J.-F.; Bruhwyler, J.; Damas, J.; Rogister, F.; Masereel, B.; Géczy, J.; Delarge, J. Modulation of the clozapine structure increases its selectivity for the dopamine D4 receptor. Eur. J. Pharmacol. 1995, 273, R1-R3.
48. Bruhwyler, J.; Liégeois, J.-F.; Chleide, E.; Rogister, F.; Damas, J.; Delarge, J.; Mercier, M. Comparative study of typical neuroleptics, clozapine and new synthesized clozapine-analogues: correlations between neurochemistry and behaviour. Behav. Pharmacol. 1992, 3, 567-579.
49. Bruhwyler, J.; Chleide, E.; Houbeau, G.; Waegeneer, N.; Mercier, M. Differentiation of haloperidol and clozapine using a complex operant schedule in the dog. Pharmacol. Biochem. Behav. 1993, 44, 181-189.
50. Bruhwyler, J.; Liégeois, J.-F.; Bergman, J.; Carey, G.; Goudie, A.; Taylor, A.; Meltzer, H. Y.; Delarge, J.; Géczy, J. JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: A review of its behavioural properties. Pharmacol. Res. 1997, 36, 255-264.
51. Ellenbroek, B. A.; Liégeois, J.-F.; Bruhwyler, J.; Cools, A. R. The effects of JL 13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia. J. Pharmacol. Exp. Ther. 2001, 298, 386-391.
52. Casey, D. E.; Bruhwyler, J.; Delarge, J.; Géczy, J.; Liégeois, J.-F. The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus nonhuman primates. Psychopharmacology 2001, 157, 228-235.
53. Liégeois, J.-F.; Bruhwyler, J.; Hendrick, J.-C.; Delarge, J.; Legros, J.-J.; Damas, J. Minimal effects of JL 13, a pyridobenzoxazepine derivative with antipsychotic potential, on circulating prolactin levels in male rats. Neurosci. Lett. 2002, 319, 49-52.
54. Phillips, S. T.; de Paulis, T.; Baron, B. M.; Siegel, B. W.; Seeman, P.; Van Tol, H. H. M.; Guan, H.-C.; Smith, H. E. Binding of 5H-dibenzo[b,e][1,4]diazepine and chiral 5H-dibenzo[a,d]cycloheptene analogues of clozapine to dopamine and serotonin receptors. J. Med. Chem. 1994, 37, 2686-2696.
55. Phillips, S. T.; de Paulis, T.; Neergaard, J. R.; Baron, B. M.; Siegel, B. W.; Seeman, P.; Van Tol, H. H. M.; Guan, H.-C.; Smith, H. E. Binding of 5H-dibenzo[a,d]cycloheptene and dibenz[b,f]-oxepin analogues of clozapine to dopamine and serotonin receptors. J. Med. Chem. 1995, 38, 708-714.
56. Seeman, P. Antipsychotic drugs, dopamine D2 receptors, and schizophrenia. In Pharmacology and Toxicology Series: Neurotransmitter Receptors in Actions of Antipsychotic Medications; Lidow, M. S., Ed.; CRC Press: New York, 2000; pp 43-63.
57. Warawa, E. J.; Migler, B. M.; Ohnmacht, C. J.; Needles, A. L.; Gatos, G. C.; McLaren, F. M.; Nelson, C. L.; Kirkland, K. M. Behavioral approach to nondyskinetic dopamine antagonists: Identification of seroquel. J. Med. Chem. 2001, 44, 372-389.
58. Cooper, S. J.; Butler, A.; Tweed, J.; Welch, C.; Raniwalla, J. Zotepine in the prevention of recurrence: A randomised, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacology 2000, 150, 237-243.
59. Steiner, G.; Franke, A.; Hädicke, E.; Lenke, D.; Teschendorf, H.-J.; Hofmann, H.-P.; Kreiskott, H.; Worstmann, W. Tricyclic epines. Novel (E)- and (Z)-11H-dibenz[b, e]azepines as potential central nervous system agents. Variation of the basic side chain. J. Med. Chem. 1986, 29, 1877-1888.
60. Fryer, R. I.; Earley, J. V.; Field, G. F.; Zally, W.; Sternbach, L. H. A synthesis of amidines from cyclic amides. J. Org. Chem. 1969, 34, 1143-1145.
61. Dupont, L.; Eyrolles, L.; Evrard, G.; Delarge, J.; Liégeois, J.-F. 8-Chloro-6(3-dimethyl(aminopropyl)amino)-11H-pyrido[2,3-b]- [1,4]benzodiazepine. Acta Crystallogr. 2002, E58, o69-o71.
62. Jilek, J. O.; Metysova, J.; Nemec, J.; Sedivy, Z.; Pomykacek, J.; Protiva, M. Potential neuroleptics: N-aralkyl, N-(aroylalkyl) and N-pyridyl derivatives of 10-piperazino-10,11-dihydrodibenzo[b,f]-thiepins. Collect. Czech. Chem. Commun. 1975, 40, 3386-3398.
63. Bürki, H. R.; Fischer, R.; Hunziker, F.; Künzle, F.; Petcher, T. J.; Schmutz, J.; Weber, H. P.; White, T. G. Dibenzo-epines: Effect of the basic side-chain on neuroleptic activity. Eur. J. Med. Chem. 1978, 13, 479-485.
64. Skoldinov, A. P.; Rayevskii, K. S.; Likhosherstov, A. M.; Stavrovskaja, A. W.; Rüger, C.; Rostock, A.; Röhnert, H. Synthese und neurologische wirkung neuer 11-substituierter 5H- dibenzo [b,e][1,4]diazepine. Pharmazie 1984, 39, 812-813.
65. Capuano, B.; Crosby, I. T.; Gable, R. W.; Lloyd, E. J. N-Piperonyl analogue of the atypical antipsychotic clozapine. Acta Crystallogr. C 2000, 56, 339-340.
66. Chakrabarti, J. K.; Horsman, L.; Hotten, T. M.; Pullar, I. A.; Tupper, D. E.; Wright, F. C. 4-Piperazinyl-10H-thieno[2,3-b][1,5]-benzodiazepines as potential neuroleptics. J. Med. Chem. 1980, 23, 878-884.
67. Bruhwyler, J.; Liégeois, J.-F.; Lejeune, C.; Rogister, F.; Delarge, J.; Géczy, J. New dibenzazepine derivatives with disinhibitory and/or antidepressant potential: Neurochemical and behavioural study in the open-field and forced swimming tests. Behav. Pharmacol. 1995, 6, 830-838.
68. Liégeois, J.-F.; Scuvée-Moreau, J.; Giesberg, I.; Damas, J.; Bruhwyler, J.; Géczy, J.; Delarge, J.; Dresse, A. Dibenzoazepine analogues: The electrophysiological properties of JL 3, a potential atypical antidepressant. Eur. J. Pharmacol. 1996, 310, 9-12.
69. Liégeois, J.-F.; Seutin, V.; Scuvée-Moreau, J.; Dresse, A.; Bruhwyler, J.; Géczy, J.; Delarge, J.; Damas, J. Effects of JL 3, a putative antidepressant, on rat noradrenergic and serotonergic systems. Eur. J. Pharmacol. 1999, 386, 211-216.
70. Hadj Tahar, A.; Bélanger, N.; Bangassoro, E.; Grégoire, L.; Bédard, P. J. Antidyskinetic effect of JL 18, a clozapine analogue, in parkinsonian monkeys. Eur. J. Pharmacol. 2000, 399, 183-186.
71. Morishita, H.; Katsuragi, T. Existence and pharmacological properties of dopamine D4 receptors in guinea pig vas deferens. Eur. J. Pharmacol. 1999, 374, 255-261.
72. Nowak, J. Z.; Zawilska, J. B.; Rosiak, J.; Kalaony, T. Melatonin biosynthesis in the retina: Effect of UV-A light. Proc. Eur. Soc. Neurochem. Meet., 11th 1997, 605-609.
73. Seeman, P.; Corbett, R.; Van Tol, H. H. M. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 1997, 16, 93-110.
74. Petcher, T. J.; Weber, H.-P. Conformations of some semirigid neuroleptic drugs. Part 1. Crystal structures of loxapine, clozapine, and HUF-2046 monohydrate {2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine, 8-chloro-11-(4-methylpiperazin-1-yl)dibenzo [b,e][1,4]diazepine, and 2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,e][1,4]diazepine monohydrate}. J. Chem. Soc., Perkin Trans. 2 1976, 1415-1420.
75. Sbit, M.; Dupont, L.; Dideberg, O.; Liégeois, J.-F.; Delarge, J. Structure de la clothiapine. Acta Crystallogr. C 1987, 43, 720-722.
76. Sbit, M.; Dupont, L.; Dideberg, O.; Liégeois, J.-F.; Delarge, J. Structure du 5-(4-méthylpipérazin-1-yl)pyrido[2,3-b]benzo-1,5- thiazépine. Acta Crystallogr. C 1988, 44, 319-321.
77. Dupont, L.; Dideberg, O.; Liégeois, J.-F.; Delarge, J. Structure du 10-(4-méthylpipérazin-1-yl)pyrido[4,3-b]benzo-1, 4-thiazépine. Acta Crystallogr. C 1991, 47, 1740-1742.
78. Ellenbroek, B. A.; Peeters, B. W.; Honig, W.; Cools, A. R. The paw test: A behavioral pardigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology 1987, 93, 343-348.
79. Ellenbroek, B. A.; Lubbers, L. J.; Cools, A. R. Activity of seroquel (ICI 204,636) in animal models for atypical properties of antipsychotics - A comparison with clozapine. Neuropsychopharmacology 1996, 15, 406-416.
80. Porsolt, R. D.; Bertin, A.; Jalfre, M. Behavioral despair in mice: A primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 1977, 229, 327-336.
81. 2 receptors. J. Pharmacol. Exp. Ther. 1993, 266, 1374-1384.
82. Wadenberg, M.-L. G.; Sills, T. L.; Fletcher, P. J.; Kapur, S. Antipsychotic-like effects of amoxapine, without catalepsy, using the prepulse inhibition of the acoustic startle reflex test in rats. Biol. Psychiatry 2000, 47, 670-676.
83. 2 occupancy. Biol. Psychiatry 1999, 45, 1217-1220.
84. Brookes, P.; Terry, R. J.; Walker, J. The chemotherapy of filariasis. Analogues of diethylcarbamazine (1-diethylcarbamoyl-4-methylpiperazine) derived from 2:4′ and 4:4′-dipiperidyl, homopiperazine, and 4-aminopiperidine. J. Chem. Soc. 1957, 3165-3172.
85. Dostert, P.; Imbert, T.; Langlois, M.; Bucher, B.; Mocquet, G. Studies on the neuroleptic benzamides. III. Synthesis and antidopaminergic properties of new 3-nortropane derivatives. Eur. J. Med. Chem. 1984, 19, 105-110.
86. 2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol. Pharmacol. 1982, 21, 301-314.
87. 1-receptor blocking properties. Eur. J. Pharmacol. 1986, 125, 333-340.
88. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.